Search results
Pages
-
- Importance of patient reported outcome measures versus clinical outcomes for breast cancer patients evaluation on quality of care
-
- Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus
-
- Integrating clinicopathological and molecular data in the breast cancer patient : towards precision medicine
-
- The influence of insulin-like Growth Factor-1-Receptor expression and endocrine treatment on clinical outcome of postmenopausal hormone receptor positive breast cancer patients: A Dutch TEAM substudy analysis
-
- The clinical prognostic value of molecular intrinsic tumor subtypes in older breast cancer patients: A FOCUS study analysis
-
- Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01)
-
- Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials
-
- Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)
-
- Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients
-
- Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients
-
- Variations in compliance to quality indicators by age for 41,871 breast cancer patients across Europe: A European Society of Breast Cancer Specialists database analysis
-
- Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach
-
- Long term effects of extended adjuvant endocrine therapy on quality of life in breast cancer patients
-
- Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial